Showing results (1-10 of 135) with videos related to
Sort By:
Pageof 14
Movement Disorders : Official Journal of the Movement Disorder Society|June 8, 2001
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literatureJ E Ahlskog, M D MuenterMayo Clinic Proceedings|October 1, 1988
Treatment of Parkinson's disease with pergolide: a double-blind studyJ E Ahlskog, M D MuenterMayo Clinic Proceedings|October 1, 1988
Pergolide: long-term use in Parkinson's diseaseJ E Ahlskog, M D MuenterNeurology|October 1, 1988
PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]: a new and effective anti-Parkinson's disease agentM D Muenter, J E Ahlskog, G Bell, et al.Archives of Neurology|May 1, 1992
Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide)J E Ahlskog, M D Muenter, P A Bailey, et al.Clinical Neuropharmacology|June 1, 1991
Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopaJ E Ahlskog, M D Muenter, P A Bailey, et al.Clinical Neuropharmacology|June 1, 1996
Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effectJ E Ahlskog, K F Wright, M D Muenter, et al.Mayo Clinic Proceedings|September 1, 1988
Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson's diseaseJ E Ahlskog, M D Muenter, P G McManis, et al.Archives of Neurology|December 1, 1994
Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergolineJ E Ahlskog, M D Muenter, D M Maraganore, et al.Neurology|October 1, 1993
Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County projectR J Uitti, J E Ahlskog, D M Maraganore, et al.Pageof 14